| Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ... The Lancet Neurology 16 (9), 701-711, 2017 | 286 | 2017 |
| Imprecise vowel articulation as a potential early marker of Parkinson's disease: Effect of speaking task J Rusz, R Cmejla, T Tykalova, H Ruzickova, J Klempir, V Majerova, ... The Journal of the Acoustical Society of America 134 (3), 2171-2181, 2013 | 265 | 2013 |
| Functional magnetic resonance imaging during deep brain stimulation: a pilot study in four patients with Parkinson's disease R Jech, D Urgošík, J Tintěra, A Nebuželský, J Krásenský, R Liščák, J Roth, ... Movement disorders: official journal of the Movement Disorder Society 16 (6 …, 2001 | 205 | 2001 |
| Monogenic variants in dystonia: an exome-wide sequencing study M Zech, R Jech, S Boesch, M Škorvánek, S Weber, M Wagner, C Zhao, ... The Lancet Neurology 19 (11), 908-918, 2020 | 154 | 2020 |
| Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy J Rusz, R Čmejla, H Růžičková, J Klempíř, V Majerová, J Picmausová, ... Journal of Neural Transmission 120, 319-329, 2013 | 101 | 2013 |
| Efficacy and safety of a standardised 500 unit dose of Dysport® (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia … J Wissel, P Kanovsky, E Ruzicka, M Bares, H Hortová, H Streitová, R Jech, ... Journal of neurology 248, 1073-1078, 2001 | 100 | 2001 |
| Diagnostic exome sequencing in early‐onset Parkinson's disease confirms VPS13C as a rare cause of autosomal‐recessive Parkinson's disease B Schormair, D Kemlink, B Mollenhauer, O Fiala, G Machetanz, J Roth, ... Clinical Genetics 93 (3), 603-612, 2018 | 88 | 2018 |
| Fear of falling has greater influence than other aspects of gait disorders on quality of life in patients with Parkinson’s disease H Brozova, J Stochl, J Roth, E Ruzicka Neuro Endocrinol Lett 30 (4), 453-457, 2009 | 85 | 2009 |
| Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics T Brücke, J Roth, I Podreka, R Strobl, S Wenger, S Asenbaum The Lancet 339 (8791), 497, 1992 | 80 | 1992 |
| Extrapyramidová onemocnění: Parkinsonova nemoc a parkinsonské syndromy E Růžička, J Roth, P Kaňovský Galen, 2000 | 78 | 2000 |
| Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study T Tykalová, J Rusz, R Čmejla, J Klempíř, H Růžičková, J Roth, E Růžička Journal of neural transmission 122, 1135-1142, 2015 | 67 | 2015 |
| Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease O Bezdicek, V Majerova, M Novak, T Nikolai, E Ruzicka, J Roth Applied Neuropsychology: Adult 20 (1), 33-40, 2013 | 66 | 2013 |
| Deep brain stimulation of the subthalamic nucleus affects resting EEG and visual evoked potentials in Parkinson's disease R Jech, E Růžička, D Urgošík, T Serranová, M Volfová, O Nováková, ... Clinical neurophysiology 117 (5), 1017-1028, 2006 | 66 | 2006 |
| Parkinsonova nemoc J Roth, M Sekyrová, E Růžička Maxdorf, 1999 | 63 | 1999 |
| Acoustic assessment of voice and speech disorders in Parkinson's disease through quick vocal test J Rusz, R Čmejla, H Růžičková, J Klempíř, V Majerová, J Picmausová, ... Movement Disorders 26 (10), 1951-1952, 2011 | 62 | 2011 |
| Sleep disturbances in untreated Parkinson’s disease J Bušková, J Klempíř, V Majerová, J Picmausová, K Šonka, R Jech, J Roth, ... Journal of neurology 258, 2254-2259, 2011 | 59 | 2011 |
| Variation of selective gray and white matter atrophy in Huntington's disease R Jech, J Klempíř, J Vymazal, J Židovská, O Klempířová, E Růžička, ... Movement disorders: official journal of the Movement Disorder Society 22 (12 …, 2007 | 59 | 2007 |
| Objective acoustic quantification of phonatory dysfunction in Huntington's disease J Rusz, J Klempíř, E Baborová, T Tykalová, V Majerová, R Čmejla, ... PloS one 8 (6), e65881, 2013 | 57 | 2013 |
| Characteristics and occurrence of speech impairment in Huntington’s disease: possible influence of antipsychotic medication J Rusz, J Klempíř, T Tykalová, E Baborová, R Čmejla, E Růžička, J Roth Journal of Neural Transmission 121, 1529-1539, 2014 | 56 | 2014 |
| Apomorphine does not influence olfactory thresholds in Parkinson's disease. J Roth, T Radil, E Růzicka, R Jech, J Tichý Functional neurology 13 (2), 99-103, 1998 | 54 | 1998 |
